Soluble amyloid precursor proteins and secretases as alzheimer's disease biomarkers

Trends in Molecular Medicine

Volumn 20, Issue 1, 2014, Pages 8-15

  Perneczky, Robert ^a,b,c   Alexopoulos, Panagiotis ^c   Kurz, Alexander ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer's disease; Amyloid precursor protein; Biomarker; Dementia; Early diagnosis; Secretase

Indexed keywords

ADAM10 ENDOPEPTIDASE; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; DISINTEGRIN; SECRETASE; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; ENZYME ACTIVITY; HETEROZYGOTE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; HUMANS; PROTEOLYSIS;

EID: 84891371279     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.10.001     Document Type: Review

References (107)

1. Jack C.R., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:257-262.
2. Lopez O.L. Mild cognitive impairment. Continuum (Minneap. Minn.) 2013, 19:411-424.
3. McKhann G.M., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:263-269.
4. McKhann G.M. Changing concepts of Alzheimer disease. JAMA 2011, 305:2458-2459.
5. Giaccone G., et al. New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurol. 2011, 10:298-299. author reply 300-301.
6. Ballard C., et al. Alzheimer's disease. Lancet 2011, 377:1019-1031.
7. Jack C.R., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
8. Hampel H., et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9:560-574.
9. Blennow K., et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
10. Herholz K., Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol. 2011, 10:667-670.
11. Dubois B., et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
12. Hansson O., et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5:228-234.
13. Rosen C., et al. Fluid biomarkers in Alzheimer's disease - current concepts. Mol. Neurodegener. 2013, 8:20.
14. Mattsson N., et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009, 302:385-393.
15. 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J. Nucl. Med. 2012, 53:59-71.
16. Bloudek L.M., et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. J. Alzheimers Dis. 2011, 26:627-645.
17. Anonymous Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group. Neurobiol. Aging 1998, 19:109-116.
18. Knopman D.S., et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
19. Beach T.G., et al. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J. Neuropathol. Exp. Neurol. 2012, 71:266-273.
20. Bateman R.J., et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
21. Ringman J.M., et al. Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers. Dement. Geriatr. Cogn. Disord. Extra 2012, 2:652-657.
22. Stomrud E., et al. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch. Neurol. 2010, 67:217-223.
23. Dickson D.W., et al. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 2011, 45:384-389.
24. Quigley H., et al. PET imaging of brain amyloid in dementia: a review. Int. J. Geriatr. Psychiatry 2011, 26:991-999.
25. Viswanathan A., Greenberg S.M. Cerebral amyloid angiopathy in the elderly. Ann. Neurol. 2011, 70:871-880.
26. Middleton L.E., et al. Neuropathologic features associated with Alzheimer disease diagnosis: age matters. Neurology 2011, 77:1737-1744.
27. Perneczky R., et al. [Cognitive reserve and its relevance for the prevention and diagnosis of dementia]. Nervenarzt 2011, 82:325-330. 332-335.
28. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol. 2012, 11:1006-1012.
29. Perneczky R., et al. Head circumference, apolipoprotein E genotype and cognition in the Bavarian School Sisters Study. Eur. Psychiatry 2012, 27:219-222.
30. Wharton S.B., et al. Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. J. Alzheimers Dis. 2011, 25:359-372.
31. Grimmer T., et al. β Amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 2009, 65:927-934.
32. De Felice F.G., et al. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol. Aging 2008, 29:1334-1347.
33. 1-42, SORL1, and tau levels in Alzheimer's disease. J. Alzheimers Dis. 2012, 28:543-552.
34. Vassar R. BACE1: the β-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 2004, 23:105-114.
35. Fukumoto H., et al. β-Secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch. Neurol. 2002, 59:1381-1389.
36. Johnston J.A., et al. Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease. Biochem. Soc. Trans. 2005, 33:1096-1100.
37. Stockley J.H., O'Neill C. Understanding BACE1: essential protease for amyloid-β production in Alzheimer's disease. Cell. Mol. Life Sci. 2008, 65:3265-3289.
38. Verheijen J.H., et al. Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay. Clin. Chem. 2006, 52:1168-1174.
39. Vassar R., et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
40. Yan R., et al. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity. Nature 1999, 402:533-537.
41. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
42. Deng Y., et al. Amyloid-β protein (Aβ) Glu11 is the major β-secretase site of β-site amyloid-β precursor protein-cleaving enzyme 1(BACE1), and shifting the cleavage site to Aβ Asp1 contributes to Alzheimer pathogenesis. Eur. J. Neurosci. 2013, 37:1962-1969.
43. Jonsson T., et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012, 488:96-99.
44. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
45. Kojro E., et al. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5815-5820.
46. Postina R., et al. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 2004, 113:1456-1464.
47. Kuhn P.H., et al. ADAM10 is the physiologically relevant, constitutive α-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010, 29:3020-3032.
48. Weskamp G., et al. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 2002, 22:1537-1544.
49. Bekris L.M., et al. Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease. Neurobiol. Aging 2011, 32. 556.e13-23.
50. Sjolander A., et al. BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease. Mol. Neurodegener. 2010, 5:37.
51. Jiang H., et al. Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease. Mol. Neurodegener. 2011, 6:69.
52. Skovronsky D.M., et al. Protein kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the trans-Golgi network. J. Biol. Chem. 2000, 275:2568-2575.
53. Randall A.D., et al. The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology 2010, 9:243-267.
54. Shin R.W., et al. Novel α-secretase cleavage of Alzheimer's amyloid β precursor protein in the endoplasmic reticulum of COS7 cells. Neurosci. Lett. 2005, 376:14-19.
55. Sankaranarayanan S., et al. In vivo β-secretase 1 inhibition leads to brain Aβ lowering and increased α-secretase processing of amyloid precursor protein without effect on neuregulin-1. J. Pharmacol. Exp. Ther. 2008, 324:957-969.
56. Lewczuk P., et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol. Psychiatry 2010, 15:138-145.
57. Gorham P., et al. Platelet α- and β-secretase activities are not significantly affected by dementia or mild cognitive impairment in Swedish patients. Curr. Alzheimer Res. 2010, 7:134-139.
58. Ueno M., et al. Transporters in the brain endothelial barrier. Curr. Med. Chem. 2010, 17:1125-1138.
59. Rosen C., et al. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease. Neuromol. Med. 2012, 14:65-73.
60. Zhong Z., et al. Levels of β-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 2007, 64:718-726.
61. Ewers M., et al. Increased CSF-BACE1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131:1252-1258.
62. Zetterberg H., et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 2008, 65:1102-1107.
63. Wu G., et al. Decrease in age-adjusted cerebrospinal fluid β-secretase activity in Alzheimer's subjects. Clin. Biochem. 2008, 41:986-996.
64. Wu G., et al. Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease. J. Neurosci. Res. 2012, 90:2247-2258.
65. Bermejo-Bescos P., et al. Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI). Neurochem. Res. 2013, 38:1415-1423.
66. Johnston J.A., et al. Platelet β-secretase activity is increased in Alzheimer's disease. Neurobiol. Aging 2008, 29:661-668.
67. Liu W.W., et al. Elevated platelet β-secretase activity in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007, 24:464-468.
68. Tsolakidou A., et al. β-Site amyloid precursor protein-cleaving enzyme 1 activity is related to cerebrospinal fluid concentrations of sortilin-related receptor with A-type repeats, soluble amyloid precursor protein, and tau. Alzheimers Dement. 2013, 9:386-391.
69. Mulder S.D., et al. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J. Alzheimers Dis. 2010, 20:253-260.
70. Ewers M., et al. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease. J. Alzheimers Dis. 2011, 25:373-381.
71. Grimmer T., et al. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol. Aging 2012, 33:2766-2773.
72. Alexopoulos P., et al. amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature. J. Alzheimers Dis. 2013, 36:401-408.
73. Bai L., et al. Elevated plasma levels of soluble TNFRs and TACE activity in Alzheimer's disease patients of Northern Han Chinese descent. Curr. Alzheimer Res. 2013, 10:57-62.
74. Qin W., et al. S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic α-secretase activity acts via selective promotion of ADAM-10. PLoS ONE 2009, 4:e4183.
75. Kim M.L., et al. Effects of TNFα-converting enzyme inhibition on amyloid β production and APP processing in vitro and in vivo. J. Neurosci. 2008, 28:12052-12061.
76. Liao Y.F., et al. Tumor necrosis factor-α, interleukin-1β, and interferon-γ stimulate γ-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J. Biol. Chem. 2004, 279:49523-49532.
77. Koenigsknecht-Talboo J., Landreth G.E. Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 2005, 25:8240-8249.
78. Chasseigneaux S., Allinquant B. Functions of Aβ, sAPPα and sAPPβ: similarities and differences. J. Neurochem. 2012, 120(Suppl. 1):99-108.
79. Lewczuk P., et al. Cerebrospinal fluid soluble amyloid-β protein precursor as a potential novel biomarkers of Alzheimer's disease. J. Alzheimers Dis. 2012, 28:119-125.
80. Perneczky R., et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 2011, 77:35-38.
81. Brinkmalm G., et al. Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Res. 2013, 1513:117-126.
82. Olsson A., et al. Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp. Neurol. 2003, 183:74-80.
83. Alexopoulos P., et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement. 2012, 8:304-311.
84. Alexopoulos P., et al. The sortilin-related receptor SORL1 and the amyloid cascade: a possible explanation for the concurrent elevation of CSF soluble APPα and APPβ in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2010, 25:542-543.
85. Chow V.W., et al. An overview of APP processing enzymes and products. Neuromol. Med. 2010, 12:1-12.
86. Perneczky R., et al. Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease. Transl. Psychiatry 2013, 3:e227.
87. Wu G., et al. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex. J. Neurosci. Res. 2011, 89:822-832.
88. Vignini A., et al. Platelet amyloid precursor protein isoform expression in Alzheimer's disease: evidence for peripheral marker. Int. J. Immunopathol. Pharmacol. 2011, 24:529-534.
89. Jiang S., et al. Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2003, 118B:99-102.
90. Mullard A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 2012, 11:657-660.
91. Siemers E.R. How can we recognize "disease modification" effects?. J. Nutr. Health Aging 2009, 13:341-343.
92. Hampel H., et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol. 2011, 95:579-593.
93. Hurko O. The uses of biomarkers in drug development. Ann. N. Y. Acad. Sci. 2009, 1180:1-10.
94. Gilman S., et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
95. Blennow K., et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch. Neurol. 2012, 69:1002-1010.
96. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
97. Mortimer J.A. The Nun Study: risk factors for pathology and clinical-pathologic correlations. Curr. Alzheimer Res. 2012, 9:621-627.
98. Valenzuela M., et al. Cognitive lifestyle and long-term risk of dementia and survival after diagnosis in a multicenter population-based cohort. Am. J. Epidemiol. 2011, 173:1004-1012.
99. Noel-Storr A.H., et al. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. Alzheimers Dement. 2013, 9:e96-e105.
100. Jack C.R., et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002, 58:750-757.
101. 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol. 2012, 124:823-831.
102. Verwey N.A., et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 2009, 46:235-240.
103. Carrillo M.C., et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 2013, 9:137-140.
104. Malpass K. Alzheimer disease: a novel biomarker to detect early-stage Alzheimer disease. Nat. Rev. Neurol. 2011, 7:420.
105. Johnson K.A., et al. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012, 2:a006213.
106. Riverol M., Lopez O.L. Biomarkers in Alzheimer's disease. Front Neurol 2011, 2:46.
107. Zhang S., et al. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int J Clin Pract 2012, 66:185-198.